Imagine the mounds of paper pushed in association with a clinical trial, then think of
invivodata.
The South Side company's founders were the first in the industry to develop a handheld patient diary to record electronic Patient Reported Outcomes (ePRO) in 1987.
Today the company is celebrating 10 years in business as an industry leader and recently anounced a partnership with Quintiles Transnational Corp., one of the largest clinical research service firms. The firm has made invivodata's technology a centerpiece of its clinical services.
With the FDA redefining the rules on how companies gather trial data in a highly regulated industry--encouraging companies to include the patient perspective during clinical research and improve how data is collected--invivodata is in the right place at the right time.
As a result, the company plans to expand this year both in Europe and the U.S. and will be hiring general administration, marketing, sales, scientific consultants and project managers. In a normally slow moving market, invivodata is projecting double digit, consistent growth this year.
"It's been nice timing in that pharma companies are paying attention and incorporating more electronics," says Tom Henson, vice president of marketing.
Invivodata's ePRO products have supported global trials in 50 different languages and countries. The technology has assisted with 275 clinical studies involving more than 90,000 patients. Allergen's Acular LS program was the first drug to be approved by the FDA with electronically collected patient data supported by invivodata.
"Pittsburgh is working out tremendously for us," says Henson. "We've got a great scientific and technology community. What makes us successful is bringing science, technology and service together and we've got a great base of talent to draw from on all three."
Writer:
Deb SmitSource: Tom Henson, invivodata
Image courtesy of invivodata